drugset / Trial / NCT02304042

Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Delivered Vaginally With at Least 2 Risk Factors for Atonic PPH: A Randomised Controlled Trial

NCT02304042

Phase 3 Completed 200 enrolled Cairo University
RandomizedParallel-groupDouble-blindPrevention

Summary

250 women will be randomly divided into 2 equal groups using computer generated random numbers. Group 1 will receive Carbetocin 100 µgm (Pabal® Ferring, UK) and group 2 will receive oxytocin 5IU (Syntocinon®, Novartis, Switzerland). Both drugs will be diluted in 10ml saline and will be given by the slowly intravenously after delivery of the anterior shoulder. The investigators will not include a control group for ethical reasons.

Timeline

Start
2014-11
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carbetocin Peptide 100 ug Intravenous
Comparator Oxytocin Peptide 5 iu Intravenous

Indications

No indication recorded.